Microbiome Health Index™ Platform, Outcomes of Rebiotix’s RBX7455 Oral Formulation To Be Featured in Rapid Fire and Poster Sessions at ASM Microbe 2018
Microbiome Health Index™ analysis of RBX7455 reveals results similar to those seen in RBX2660 clinical trials
Download this press release (274 KB).
ROSEVILLE, MN – June 08, 2018 — Rebiotix Inc. announced today that findings from Microbiome Health Index™ platform measurements of patients treated with RBX7455, the company’s lyophilized, room-temperature stable oral capsule microbiota-based drug, will be presented in podium and poster presentations at the American Society for Microbiology (ASM) Microbe 2018 meeting, June 7-11 in Atlanta.
The MHI platform was designed to quantify the changes in patient microbiomes over time; in the upcoming data set, presented by Rebiotix’s Chief Scientific Officer, Ken Blount, Ph.D., MHI outcomes of patients who received RBX7455 exhibited similar trends to patients treated with RBX2660, Rebiotix’s Phase 3 microbiota drug candidate. Additionally, pre-treatment MHIs were similar to baseline MHIs measured in RBX2660 trials. This provides further strength to the usefulness of the measurement as a reliable marker of shifts in the microbiome after treatment.
The schedule of presentations at ASM Microbe 2018 is as follows: